- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07941063
Multimodal Ultrasound for Lymphoma Classification and Treatment Response Prediction
Multimodal Ultrasound-Based Intelligent Classification and Treatment Response Prediction in the Dynamic Evolution of Lymphoma
This prospective, multicenter, observational cohort study aims to evaluate whether multimodal ultrasound can support the noninvasive classification of lymphoma and the early prediction of treatment response.
Adults with newly diagnosed and previously untreated lymphoma will undergo standardized multimodal ultrasound examinations before treatment, after the first treatment cycle, after the fourth treatment cycle, and during follow-up. Ultrasound examinations will include B-mode ultrasound, color Doppler flow imaging, contrast-enhanced ultrasound, super-resolution contrast-enhanced ultrasound, and ultrasound viscoelasticity imaging. Clinical, laboratory, pathological, molecular, treatment, and follow-up information will also be collected.
The study will investigate differences in ultrasound characteristics among lymphoma subtypes, evaluate changes in ultrasound features during treatment, and develop and validate prediction models integrating imaging and clinical information. The main hypothesis is that multimodal ultrasound features and their early treatment-related changes reflect the biological heterogeneity of lymphoma and can improve noninvasive lymphoma classification and early prediction of treatment response.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, multicenter, observational cohort study of adults with newly diagnosed, previously untreated lymphoma. The study plans to prospectively enroll approximately 2,000 participants across participating centers.
Standardized multimodal ultrasound data will be collected at predefined time points, including before treatment, after the first treatment cycle, after the fourth treatment cycle, and during subsequent follow-up. Imaging modalities include B-mode ultrasound (BUS), color Doppler flow imaging (CDFI), contrast-enhanced ultrasound (CEUS), super-resolution contrast-enhanced ultrasound (SR-CEUS), and ultrasound viscoelasticity imaging (UVE). Clinical and laboratory information, treatment information, pathological diagnosis, immunohistochemical findings, molecular and genetic test results, and follow-up information will also be collected.
The study will first characterize multimodal ultrasound phenotypes across lymphoma categories, including Hodgkin lymphoma and non-Hodgkin lymphoma, indolent and aggressive non-Hodgkin lymphoma, and common pathological subtypes. Longitudinal changes in ultrasound features during treatment will then be evaluated to identify imaging characteristics associated with treatment response.
Using the collected multimodal imaging and clinical data, statistical and machine-learning approaches will be used to develop and validate models for lymphoma classification and early treatment-response prediction. Model development will incorporate imaging features from multiple ultrasound modalities together with relevant clinical information. Model performance will be evaluated using measures of discrimination, calibration, and clinical utility, as appropriate.
The overall objective is to determine whether multimodal ultrasound can provide a noninvasive and repeatable approach for characterizing lymphoma heterogeneity and for identifying treatment response at an earlier stage of therapy.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jie Yu, PhD
- Phone Number: 01066937110
- Email: jiemi301@163.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100853
- Recruiting
- Chinese PLA General Hospital
-
Contact:
- Jie Yu, PhD
- Phone Number: +8601066937110
- Email: jiemi301@163.com
-
Principal Investigator:
- Jie Yu, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adults with histopathologically confirmed, newly diagnosed, previously untreated lymphoma who present to participating study centers and have at least one lesion suitable for standardized multimodal ultrasound evaluation will be prospectively enrolled.
Description
Inclusion Criteria:
- Age 18 years or older.
- Histopathologically confirmed lymphoma.
- Newly diagnosed and previously untreated, with no prior radiotherapy, chemotherapy, targeted therapy, immunotherapy, or other systemic antitumor treatment before enrollment.
- At least one superficial or otherwise accessible lesion that can be clearly evaluated by ultrasound, such as a cervical, axillary, or inguinal lymph node, with an adequate acoustic window allowing stable acquisition of all five ultrasound modalities.
- Expected survival of more than 3 months.
- No contraindication to the use of ultrasound contrast agents.
- Willingness to undergo multimodal ultrasound examinations before, during, and after treatment and provision of written informed consent.
Exclusion Criteria:
- Target lesion located too deeply or obscured by gas or bone, preventing acquisition of a stable ultrasound imaging plane.
- Known history of hypersensitivity to any component of the ultrasound contrast agent (sulfur hexafluoride microbubbles).
- Known right-to-left cardiac shunt, severe pulmonary hypertension with pulmonary artery pressure greater than 90 mmHg, or uncontrolled hypertension.
- Acute respiratory distress syndrome or severe respiratory insufficiency.
- Unstable angina or acute myocardial infarction within the previous 1 week.
- Pregnancy or breastfeeding.
- Inability, in the investigator's judgment, to cooperate with the complete examination procedure or complete the required follow-up.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Newly Diagnosed Untreated Lymphoma Cohort
Adults with pathologically confirmed, newly diagnosed, previously untreated lymphoma who undergo longitudinal multimodal ultrasound examinations and clinical follow-up according to the study protocol. |
Participants undergo standardized multimodal ultrasound examinations including B-mode ultrasound (BUS), color Doppler flow imaging (CDFI), contrast-enhanced ultrasound (CEUS), super-resolution contrast-enhanced ultrasound (SR-CEUS), and ultrasound viscoelasticity imaging (UVE). Examinations are performed at predefined study time points, including before treatment, after the first treatment cycle, after the fourth treatment cycle, and during follow-up. The imaging findings are collected for lymphoma classification and treatment-response prediction. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the Receiver Operating Characteristic Curve for Differentiating Hodgkin Lymphoma From Non-Hodgkin Lymphoma
Time Frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model for distinguishing Hodgkin lymphoma from non-Hodgkin lymphoma, using histopathological diagnosis as the reference standard. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Area Under the Receiver Operating Characteristic Curve for Differentiating Indolent From Aggressive Non-Hodgkin Lymphoma
Time Frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model for distinguishing indolent from aggressive non-Hodgkin lymphoma, using histopathological classification as the reference standard. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Area Under the Receiver Operating Characteristic Curve for Predicting Complete Response After the Fourth Treatment Cycle Using First-Cycle Multimodal Ultrasound
Time Frame: After completion of Cycle 1 and Cycle 4 (each cycle is 21 or 28 days, depending on the regimen; approximately 3-4 weeks and 12-16 weeks after treatment initiation, respectively).
|
The area under the receiver operating characteristic curve (AUC) will be used to evaluate the ability of the multimodal ultrasound model to predict complete response (CR) after completion of Cycle 4, using ultrasound features obtained after completion of Cycle 1. Complete response will be assessed by PET/CT or CT according to the study protocol. Each treatment cycle is scheduled to last 21 or 28 days, depending on the prescribed first-line regimen. Assessments are linked to completion of the relevant treatment cycle; the estimated calendar times assume no treatment delays. |
After completion of Cycle 1 and Cycle 4 (each cycle is 21 or 28 days, depending on the regimen; approximately 3-4 weeks and 12-16 weeks after treatment initiation, respectively).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity of the Multimodal Ultrasound Model for Identifying Hodgkin Lymphoma
Time Frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The percentage of participants with histopathologically confirmed Hodgkin lymphoma who are correctly classified as having Hodgkin lymphoma by the multimodal ultrasound model. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Specificity of the Multimodal Ultrasound Model for Identifying Hodgkin Lymphoma
Time Frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The percentage of participants with histopathologically confirmed non-Hodgkin lymphoma who are correctly classified as not having Hodgkin lymphoma by the multimodal ultrasound model. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Sensitivity of the Multimodal Ultrasound Model for Identifying Aggressive Non-Hodgkin Lymphoma
Time Frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The percentage of participants with histopathologically confirmed aggressive non-Hodgkin lymphoma who are correctly classified as having aggressive non-Hodgkin lymphoma by the multimodal ultrasound model. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Specificity of the Multimodal Ultrasound Model for Identifying Aggressive Non-Hodgkin Lymphoma
Time Frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The percentage of participants with histopathologically confirmed indolent non-Hodgkin lymphoma who are correctly classified as not having aggressive non-Hodgkin lymphoma by the multimodal ultrasound model. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Classification Accuracy of the Multimodal Ultrasound Model for Common Lymphoma Subtypes
Time Frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The proportion of participants whose lymphoma subtype is correctly classified by the multimodal ultrasound model, using histopathological diagnosis as the reference standard. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Correlation Between Multimodal Ultrasound Parameters and Tumor Cell Density
Time Frame: At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
|
The association between quantitative multimodal ultrasound parameters and tumor cell density determined by pathological assessment will be evaluated using correlation analysis. |
At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
|
|
Correlation Between Multimodal Ultrasound Parameters and Pathological Microvessel Density
Time Frame: At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
|
The association between quantitative multimodal ultrasound parameters and microvessel density determined by pathological assessment will be evaluated using correlation analysis. |
At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
|
|
Concordance Index of the Multimodal Ultrasound Model for Predicting 2-Year Progression-Free Survival
Time Frame: From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed through 24 months after enrollment.
|
The prognostic performance of the multimodal ultrasound model for predicting 2-year progression-free survival (PFS) will be evaluated using the concordance index (C-index). PFS is defined as the time from the date of initial histopathological diagnosis of lymphoma to the first documented disease progression, relapse, or death from any cause, whichever occurs first. |
From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed through 24 months after enrollment.
|
|
Concordance Index of the Multimodal Ultrasound Model for Predicting 2-Year Overall Survival
Time Frame: From enrollment to death from any cause, assessed through 24 months after enrollment.
|
The prognostic performance of the multimodal ultrasound model for predicting 2-year overall survival (OS) will be evaluated using the concordance index (C-index). OS is defined as the time from the date of initial histopathological diagnosis of lymphoma to death from any cause. |
From enrollment to death from any cause, assessed through 24 months after enrollment.
|
|
Comparison of Area Under the Receiver Operating Characteristic Curves Between the Multimodal Ultrasound Model and Radiologists
Time Frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model will be compared with that of radiologists for lymphoma classification, using histopathological diagnosis as the reference standard. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Incidence of Study Ultrasound-Related Adverse Events
Time Frame: From enrollment through 24 months after enrollment. Record ultrasound-related adverse events throughout follow-up; observe participants for 15-20 minutes after each contrast-enhanced ultrasound examination.
|
The number and proportion of participants experiencing adverse events related to study ultrasound examinations, particularly contrast-enhanced ultrasound, will be recorded. Contrast-agent-related adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Serious adverse reactions will also be documented. |
From enrollment through 24 months after enrollment. Record ultrasound-related adverse events throughout follow-up; observe participants for 15-20 minutes after each contrast-enhanced ultrasound examination.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jie Yu, PhD, Chinese PLA General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2026-532
- U25C2048 (Other Grant/Funding Number: National Natural Science Foundation of China)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.